PMID-34877934 – FOXO4-DRI Radiosensitizes NSCLC and Reduces Pulmonary Fibrosis
Meng J et al. "FOXO4-DRI alleviates radiation-induced pulmonary fibrosis by enhancing the radiosensitivity of non-small cell lung cancer," JCI Insight, 2021;6(24):e146334. doi:10.1172/jci.insight.146334
Quick Reference
| Property | Value |
|---|---|
| PMID | 34877934 |
| DOI | 10.1172/jci.insight.146334 |
| Year | 2021 |
| Journal | JCI Insight |
| Study Type | Animal in vivo + In vitro |
| Evidence Level | V |
| Sample | NSCLC cell lines, mouse lung cancer and pulmonary fibrosis models |
| Peptide(s) Studied | FOXO4-DRI |
Key Findings
- FOXO4-DRI enhanced the radiosensitivity of non-small cell lung cancer (NSCLC) cells, making radiation therapy more effective at lower doses
- Simultaneously, FOXO4-DRI reduced radiation-induced pulmonary fibrosis — a major dose-limiting toxicity of thoracic radiation therapy
- The dual effect (enhanced tumor killing + reduced normal tissue toxicity) represents an ideal therapeutic window expansion for radiation oncology
- Mechanistically, FOXO4-DRI selectively eliminated radiation-induced senescent cells in both tumor and normal lung tissue
- In the tumor, senescent cancer cells cleared by FOXO4-DRI would otherwise survive and potentially re-enter the cell cycle (therapy resistance)
- In normal lung tissue, radiation-induced senescent fibroblasts drive pulmonary fibrosis through SASP; their elimination by FOXO4-DRI prevented fibrotic remodeling
- Published in JCI Insight, a high-impact translational research journal
Study Design
Combined in vitro and in vivo study. In vitro: NSCLC cell lines (A549, H460) irradiated with and without FOXO4-DRI treatment; assessed for radiosensitivity (clonogenic assays), apoptosis, and senescence markers. In vivo: mouse models of radiation-induced lung cancer and radiation-induced pulmonary fibrosis treated with FOXO4-DRI. Endpoints included tumor volume, pulmonary fibrosis scoring (Ashcroft score), and senescent cell quantification.
Limitations
- Preclinical study with no human data
- Mouse radiation models may not fully recapitulate human thoracic radiation biology
- Optimal timing of FOXO4-DRI relative to radiation fractions not defined
- Long-term consequences of senescent cell clearance in irradiated tissues unknown
- Interaction with concurrent chemotherapy (chemoradiation) not studied
Clinical Relevance
This study positions FOXO4-DRI as a potential radiation sensitizer and radioprotector simultaneously — a rare and highly valuable therapeutic property. For lung cancer patients receiving radiation therapy, FOXO4-DRI could enhance tumor control while reducing the incidence of radiation-induced pulmonary fibrosis, a devastating long-term complication. This dual role makes FOXO4-DRI particularly relevant for thoracic oncology and supports its development as a cancer therapy adjunct alongside its established anti-aging senolytic properties.
Related
#research #animal-in-vivo #evidence-level-V #cancer